Lanka Diagnostics Limited (LDL)
LDL sees an enormous opportunity to work in partnership with an investor to cater to the demands of producing medicine for an ageing and growing Sri Lankan market, through a 15-year buy-back guarantee agreed by the State Pharmaceutical Manufacturing Corporation (SPMC) for 60% of the production. The investor is offered 65% of the equity stake in the company.
SPMC is the line agency of the Ministry of Health with the exclusive mandate to manufacture and supply pharmaceutical products to the Government of Sri Lanka.
The planned manufacturing capacity will be 1.4 billion tablets per year from which, LDL shall supply a minimum of 840 million to SPMC.
Further, the partnership endows upon LDL the use of the SPMC Trademark for all its products domestically and internationally.
The production process will use WHO, EUGMP & ISO 9000:2018 quality standards in operating & producing Pharmaceuticals, which will be a 1st-time experience for a Sri Lankan user, thus enhancing the quality of drugs supplied to the market. All manufacturing machinery will be imported as per European standards to ensure quality is maintained at all levels.
|LOCATION :||Sri Lanka|
|PROJECT VALUE :||USD 15.5 Mn|
|INVESTMENT TYPE :||Equity Investment|
|INTERNAL RATE OF RETURN :||29.5%|
|OPPORTUNITY CODE :||VBS/OP/01072022/0525/X_2|